Octave Bioscience, Inc., a commercial stage precision medicine company pioneering biomarker driven solutions for multiple sclerosis, Parkinson's disease and other neurodegenerative diseases today ...

The launch of USA-based Poplar Therapeutics has been announced, alongside a $50 million Series A financing led by SR One, ...

Don't miss the Announcement Trailer for Sprint City, a fast-paced competitive 2D platformer developed by Second Stage Studio.

Poplar Therapeutics Launches With $50M Series A to Advance a New Class of Anti-IgE Therapy for Multiple Atopic Conditions ...

DES MOINES, Iowa, Jan. 7, 2026 /PRNewswire/ -- BioSpace, the leading life sciences news and careers site, has announced its 2026 selections for the industry's most promising up-and-coming companies.

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Skye Biosciences, Inc. ("Skye" or the "Company") and reminds investors of the January 16, 2026 ...

HMBD-501 is a HER3-targeted ADC with a differentiated mechanism of action, engineered by Hummingbird Bioscience for optimal safety and efficacy ...

The company’s first-in-class and potential best-in-class therapeutics promise to be both effective and organ-protective and ...

Skye is planning to initiate a Phase 2b clinical trial in obesity for nimacimab with ENHANZE in the middle of 2026. This study will also assess the combination of nimacimab and a GLP-1R agonist.

HONG KONG SAR - EQS Newswire - 30 December 2025 - Uni-Bio Science Group Limited ("Uni-Bio Science Group", "Uni-Bio" or "the ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025, both dates inclusive (the ...

Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) just unveiled an announcement. Shanghai Henlius Biotech has renewed its property leasing ...